The Beginner’s Guide to Growth Hormone Peptides

You used to recover like it was a setting, not a project. Hard session, real sleep, next morning you were back.

Sometime after thirty that setting starts slipping. Joints feel older than the calendar. Sleep happens and still doesn’t restore you. Muscle takes longer to earn and leaves faster. A midsection that used to ignore pizza starts keeping receipts.

People call that “getting older” and stop asking what changed.

What changed is the pulse. Your pituitary already knows how to release growth hormone in bursts timed to your deepest sleep. It just does it less as you get older — and stress, poor sleep, and time blunt the signal further.

Population data put that decline on the order of roughly 10–15% per decade after about age 30. That is not your personal HGH number. It is a sketch of a system that used to spike hard at night and now spikes quieter.

• ~20s Peak output
• ~30s ~85%
• ~40s ~70%
• ~50s ~55%

Illustrative population sketch — about 10–15% per decade after ~30. Not an individual’s lab result, and not a guaranteed linear drop.

In the past, the only lever that got talked about was injecting synthetic growth hormone — expensive, tightly controlled, and easy to overrun because you are pouring hormone in instead of asking the gland to work.

Today the conversation is growth hormone peptides. Secretagogues. Tiny amino-acid chains that signal the pituitary to make and release more of its own supply.

They are not one thing. That is the whole beginner mistake.

CJC-1295, Ipamorelin, and Tesamorelin are compounded or prescription GH-axis tools managed through a licensed prescribing and monitoring provider. I don’t prescribe them. My job is the foundation side — sleep, training load, protein, and the mechanical work that gives any GH-axis signal something to convert into.

Replacement vs a signal

Synthetic HGH is replacement. You supply the hormone. The gland does not have to do the job for the duration of use. Feedback still exists — rising GH and IGF-1 put a brake on your own output while the exogenous signal is in play. That is not “permanent shutdown.” It is the axis doing what it is built to do.

Growth hormone peptides are a different conversation. They ask your pituitary to pulse its own GH. Think of it as a software update for that axis, not a hormone drip from outside.

Because the body is still making the hormone, the pulse still has to clear the same brakes — somatostatin, sleep quality, insulin status, inflammation. That is the point. You do not get to skip the system. You get to work it.

Two signals, one gland

The alphabet soup — CJC, Ipamorelin, Tesamorelin, Sermorelin, GHRP-2, GHRP-6 — collapses into one picture.

To get a large, youthful-style GH pulse, two different receptor paths on the same gland are often used together:

Path 1 — GHRH (growth hormone-releasing hormone). Tells somatotrophs in the anterior pituitary to make and release GH. The names you will see: CJC-1295 (No DAC) and Tesamorelin.

Path 2 — GHRP / secretagogue. Hits the ghrelin receptor (GHSR) and, in the peptide-community model, lowers the somatostatin brake so the pulse can actually leave the gland. The name you will see: Ipamorelin.

GHRH path and secretagogue path enter the pituitary from opposite sides and converge into a growth hormone pulse

Path 1 · GHRH

CJC-1295 No DAC · Tesamorelin

Pituitary

one gland

Path 2 · secretagogue

Ipamorelin · GHSR / GHRP

GH pulse

• Make the signal

  GHRH analogs tell the gland to synthesize and release growth hormone.

• Let the pulse leave

  A selective secretagogue works a second receptor path so the pulse is not sitting behind the somatostatin brake.

They are not one word. They are two jobs. Combining a GHRH analog with a secretagogue is described as synergistic — greater than either path alone — because you are not stacking two copies of the same signal. You are using two receptor pathways at once.

That is receptor biology, not a mandate that everyone must run both. It is why the names get said together.

Three compounds, three jobs

You do not need ten vials. Most of the useful GH-axis conversation for beginners lives in three compounds — and they are not interchangeable.

Ipamorelin — the selective trigger

Ipamorelin is a third-generation GH-releasing peptide. It stimulates the pituitary’s ghrelin receptor to trigger endogenous GH release.

Older GHRPs like GHRP-6 and GHRP-2 can elevate cortisol, prolactin, and appetite alongside the GH pulse. GHRP-6 reliably produces pronounced hunger within minutes and raises prolactin and cortisol. GHRP-2 raises cortisol to a lesser but still notable degree.

Ipamorelin produces a comparable GH pulse without the same degree of prolactin, cortisol, or appetite elevation in most users. That is selectivity — not “zero hunger, zero hormone drama.” Receptor biology, not a marketing halo.

It has a short half-life. Spike, then fade. Your body can regulate a brief pulse. It struggles to regulate a sustained flood.

CJC-1295 No DAC — the short GHRH pulse

CJC-1295 is a synthetic GHRH analog. It binds GHRH receptors on pituitary somatotrophs and stimulates GH release.

Two versions exist, and they are not the same drug with a nickname.

Without DAC (also called Mod GRF 1-29) has a short half-life — roughly 30 minutes. It mimics the body’s burst pattern: sharp pulse, then gone.

With DAC (Drug Affinity Complex) binds albumin and extends half-life to roughly eight days. That is a sustained, non-pulsatile background elevation — not the rhythm the gland is built around.

The no-DAC version preserves pulsatility. The with-DAC version trades pulsatility for duration. That trade is the whole argument. If someone hands you “CJC-1295” without saying which, you do not know what you are talking about yet.

Tesamorelin — a GHRH analog with a narrow label

Tesamorelin is also a GHRH analog. It is not “CJC, but stronger for abs.”

It received FDA approval in 2010 (brand name Egrifta) to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy on antiretroviral therapy. That is a specific population and a specific indication. The labeled product is not indicated for weight-loss management in the general population, and long-term cardiovascular safety in that broader use is not established.

In the labeled-population trials, visceral fat fell versus placebo over about six months. Those numbers stay in that population. They are not a license to market tesamorelin as a belly-fat peptide for everyone with a waistline.

Compounded tesamorelin in the peptide world sits on a different regulatory footing than the branded indication. Same analog class. Not the same paperwork. Your prescribing provider’s oversight is the point, not a forum protocol.

• Ipamorelin

  Signals: Selective GHRP / GHSR trigger.

  Footing: Compounded; community and early data favor less cortisol, prolactin, and appetite than GHRP-2/6.

  Does not prove: That it is “the safest peptide on the planet,” or that a pulse equals fat loss.

• CJC-1295 No DAC

  Signals: Short GHRH pulse (~30 min).

  Footing: Compounded; pulsatility is the design, not a ranking.

  Does not prove: That “CJC” without specifying DAC vs No DAC is a complete order.

• Tesamorelin

  Signals: GHRH analog.

  Footing: FDA-approved (2010) for excess abdominal fat in HIV-associated lipodystrophy — not for general weight loss.

  Does not prove: That it is a general-population visceral-fat drug.

Roles, not a ranking. Treatment decisions stay with the prescribing provider.

Insulin and a GH pulse do not share the stage well

If you take one mechanism away from this guide, take this one:

A high-insulin, just-fed state is a poor backdrop for a growth hormone pulse. Insulin and GH tend to compete. That is physiology, not a countdown timer. When the signal gets timed — and whether it gets timed at all — stays with the prescribing provider.

This is not an injection recipe. It is why expecting a GH-axis signal to land clean on top of a heavy meal is working against the physiology the vial is aimed at.

Just fed / high insulin

A high-insulin backdrop is a poor stage for the pulse the peptide is trying to ask for.

Lower insulin / sleep

Slow-wave sleep is when the gland already wants to pulse. Mechanism — not an injection clock.

What is usually not worth the slot

Do not reprint a skip list here. The dedicated post is The 5 Most Overrated Peptides. The GH-relevant version, in one pass:

Sermorelin is the original 1990s GHRH analog. Short half-life, weaker pulse than later analogs, tachyphylaxis showing up in community use. The modern short-acting GHRH conversation is CJC-1295 No DAC.

GHRP-6 / GHRP-2 still pulse GH. They also bring hunger and stress-hormone noise Ipamorelin was designed to avoid. Different receptor manners, not nostalgia.

AOD-9604 is a C-terminal HGH fragment that went through human obesity trials and failed to produce clinically meaningful weight loss in its major Phase 2b program. Unmodified HGH fragment 176–191 is a related idea with even less controlled human efficacy data. Do not lump them as “zero human data.” One failed a real trial. The other never earned one. Neither is a stand-in for tesamorelin’s labeled indication or for a GLP-1 when fat loss is actually the job.

Sleep is the timing mechanism, not a footnote

Most of those GH pulses happen during slow-wave sleep. A GH-axis protocol run on three fragmented hours with a screen in your face until midnight is fighting its own mechanism.

A single IGF-1 blood draw is a snapshot of a system that spikes and valleys. Low IGF-1 on one lab does not automatically mean you need GH-axis intervention. Inadequate protein, chronic stress, systemic inflammation, and poor sleep all suppress downstream signaling independent of how much GH the pituitary is actually releasing.

If you are on a secretagogue protocol from your prescribing provider but sleeping five hours, eating 60 grams of protein, and skipping resistance training, the gland may still pulse. Those pulses have nothing useful to build with.

The same rule applies to tissue-repair peptides like BPC-157 and TB-500: signal without foundations underperforms. Chemical signals and mechanical stress are the same recovery problem from two directions.

Informed protocols beat random vials. Pro-peptide, pro-foundation.

What to actually watch for

Water retention is a recognized GH-pathway side effect — GH/IGF-1 physiology, usually transient, and one reason people notice a change in the first weeks that is not fat loss.

Pituitary sensitivity declines with age. Somatostatin rises. What responded at 35 may not respond the same at 55. That is not failure. It is the brake pedal getting heavier.

Regulatory status is not a moral ranking. Tesamorelin has a labeled indication. Compounded CJC-1295 and Ipamorelin do not sit in that same FDA category. That does not make them worthless. It means sourcing, identity, and monitoring matter more — not less. For COAs, endotoxin, and batch tracking, see the peptide safety blueprint.

Reactivity is possible. A subset of people get mast-cell or histamine-type reactions to GH secretagogues — flushing, palpitations, injection-site irritation, and in rare documented cases more serious systemic reactions. That pattern is discussed as a possible marker of immune dysregulation in the person, not automatically a dirty vial. If it happens, that is a provider conversation. Anything that feels like a systemic emergency is an ER call.

FAQ

Is HGH the same as a secretagogue?

No. HGH is the hormone. Secretagogues ask your pituitary to release its own. Replacement versus a pulse. Different feedback, different risk shape, different paperwork.

Will GH peptides shut down my natural production?

They work inside the same feedback loops the axis already uses. That is not the same as “zero suppression, forever.” Exogenous HGH raises circulating GH/IGF-1 and temporarily suppresses your own output for the duration of use. Secretagogues stay on the ask-the-gland side of that line. Neither is a morality play, and neither is a promise that the axis is untouched.

Is tesamorelin a general fat-loss medication?

No. The FDA indication is excess abdominal fat in HIV-associated lipodystrophy. It is not indicated for weight-loss management in the general population. Visceral-fat data from that labeled use do not automatically transfer to “stubborn belly fat” in otherwise healthy adults.

Are there oral options if someone hates needles?

Injections remain the absorption standard for these peptides. MK-677 (ibutamoren) is an oral ghrelin-receptor agonist — a small molecule, not a peptide. It can raise GH/IGF-1. It is also associated with appetite, water retention, and effects on cortisol, prolactin, and glucose handling. It is not a needle-free Ipamorelin. If that conversation is on the table, it belongs with the prescribing provider, not a capsule-as-shortcut FAQ.

The part the vial does not do for you

You do not have to treat slower recovery, thinner sleep, and a changing midsection as a personality flaw. You also do not have to treat a GH peptide as a personality transplant.

Keep the map simple. Know which signal you are using. Know whether you are replacing the hormone or asking the gland. Know that tesamorelin’s label is not a spa menu. Give the pulse a night of real sleep, enough protein, and some actual loading.

I work with people sorting the structural side — alignment, loading, recovery tech, sleep and training foundations — alongside whatever peptide protocol their provider has them on. I make sure the biological signal has somewhere to land.

If you want help sorting what your body is actually asking for on that foundation side — that’s the conversation I have every week. Work with me.